Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease

Liatermin did not confer the predetermined level of clinical benefit to patients with PD despite increased (18)F-dopa uptake. It is uncertain whether technical differences between this trial and positive open-label studies contributed in any way this negative outcome.